Suppression of ps20 expression in the rat uterus by tamoxifen and estrogens

Endocrinology

Volumn 146, Issue 5, 2005, Pages 2388-2396

  Hung, Huynh ^a  

^a DIVISION OF MEDICAL ONCOLOGY   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; COMPLEMENTARY DNA; ESTROGEN; FULVESTRANT; PROTEIN PS20; TAMOXIFEN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CELL STRAIN MCF 7; ESTRUS CYCLE; FEMALE; GENE; GENE CONTROL; GENE EXPRESSION; GENE ISOLATION; GENE LOCATION; GENETIC TRANSFECTION; GROWTH INHIBITION; HEART; IMMUNOHISTOCHEMISTRY; INHIBITION KINETICS; INVOLUTION; LUNG; MESENCHYME CELL; MOLECULAR WEIGHT; NONHUMAN; OVARIECTOMY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN ISOLATION; PROTEIN SECRETION; PS20 GENE; RAT; SMOOTH MUSCLE; UPREGULATION; UROGENITAL SINUS; UTERUS;

ANIMALS; CULTURE MEDIA, CONDITIONED; EPITHELIAL CELLS; ESTRADIOL; ESTROGEN ANTAGONISTS; ESTROGENS; ESTROUS CYCLE; FEMALE; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; LUNG; MUSCLE, SMOOTH; MYOCARDIUM; OVARIECTOMY; POLYMERASE CHAIN REACTION; PROTEINS; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT PROTEINS; TAMOXIFEN; TRANSFECTION; UTERUS;

EID: 17744398454     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/en.2004-1525     Document Type: Article

References (26)

1. Jensen EV, DeSombre ER 1972 Mechanism of action of the female sex hormones. Annu Rev Biochem 41:203-230
2. Anderson JN, Peck Jr EJ, Clark JH 1975 Estrogen-induced uterine responses and growth: relationship to receptor estrogen binding by uterine nuclei. Endocrinology 96:160-167
3. Katzenellenbogen BS, Gorski J 1975 Biochemical actions of hormones. New York: Academic Press
4. Clarke R, Leonessa F, Welch JN, Skaar TC 2001 Cellular and molecular pharmacology of antiestrogen action and resistance. Pharmacol Rev 53:25-71
5. Jordan VC, Morrow M 1999 Tamoxifen, raloxifene, and the prevention of breast cancer. Endocr Rev 20:253-278
6. Powles TJ, Chang J 1997 Chemoprevention of breast cancer: why is tamoxifen not the answer? Endocr Relat Cancer 4:135-139
7. Fornander T, Cedermark B, Mattsson S, Skoog L, Theve T, Askergren J, Rutqvist LE, Glas U, Silfversward C, Somell A, Wilking N, Hjalmar ML 1989 Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet 117-120
8. Huynh H, Pollak M 1993 IGF-1 gene expression in the uterus is stimulated by tamoxifen and inhibited by the pure antiestrogen ICI 182780. Cancer Res 53:5585-5588
9. Huynh H, Ng CY, Lim KB, Ong CK, Ong CS, Tran E, Tuyen Nguyen TT, Chan TW 2001 Induction of UO-44 gene expression by tamoxifen in the rat uterus and ovary. Endocrinology 142:2985-2995
10. Huynh H, Pollak M 1994 Uterotrophic actions of estradiol and tamoxifen are associated with inhibition of uterine IGF binding protein 3 gene expression. Cancer Res 54:3115-3119
11. Larsen M, Ressler SJ, Lu B, Gerdes MJ, McBride L, Dang TD, Rowley DR 1998 Molecular cloning and expression of ps20 growth inhibitor: a novel WAP-type "four-disulfide core" domain protein expressed in smooth muscle. J Biol Chem 273:4574-4584
12. Robaire B, Ewing LL, Irby DC, Desjardins C 1979 Interaction of testosterone and estradiol-17β on the reproductive tract of the male rat. Biol Reprod 21:455-463
13. Huynh H, Chow PK, Ooi LL, Soo KC 2002 A possible role for insulin-like growth factor-binding protein-3 autocrine/paracrine loops in controlling hepatocellular carcinoma cell proliferation. Cell Growth Differ 13:115-122
14. Ong CK, Ng CY, Leong C, Ng CP, Foo KT, Tan PH, Huynh H 2004 Genomic structure of human OKL38 gene and its differential expression in kidney carcinogenesis. J Biol Chem 279:743-754
15. Huynh H, Yang X, Pollak M 1996 Estradiol and antiestrogens regulate a growth inhibitory insulin-like growth factor binding protein 3 autocrine loop in human breast cancer cells. J Biol Chem 271:1016-1021
16. Huynh H, Tetenes E, Wallace L, Pollak M 1993 In vivo inhibition of insulin-like growth factor-I gene expression by tamoxifen. Cancer Res 53:1727-1730
17. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N 1998 Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90:1371-1388
18. Wakeling AE, Bowler J 1988 Novel antioestrogens without partial agonist activity. J Steroid Biochem 31:645-653
19. Fornander T, Rutqvist LE, Wilking N 1991 Effects of tamoxifen on the female genital tract. Ann NY Acad Sci 622:469-476
20. Andersson M, Storm HH, Mouridser HT 1991 Incidence of new primary cancers after adjuvant tamoxifen therapy and radiotherapy for early breast cancer. J Natl Cancer Inst 83:1013-1017
21. Magriples U, Naftolin F, Schwartz PE, Carcangiu ML 1993 High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients. J Clin Oncol 11:485-490
22. Swenerton KD 1980 Treatment of advanced endometrial adenocarcinoma with tamoxifen. Cancer Treat Rep 64:805-811
23. Jordan VC, Gottardis MM, Satyaswaroop PG 1991 Tamoxifen-stimulated growth of human endometrial carcinoma. Ann NY Acad Sci 622:439-446
24. Dilts PV, Hopkins MP, Chang AE, Cody RL 1992 Rapid growth of leiomyoma in patient receiving tamoxifen. Am J Obstet Gynecol 166:167-168
25. McAlhany SJ, Ayala GE, Frolov A, Ressler SJ, Wheeler TM, Watson JE, Collins C, Rowley DR 2004 Decreased stromal expression and increased epithelial expression of WFDC1/ps20 in prostate cancer is associated with reduced recurrence-free survival. Prostate 61:182-191
26. McAlhany SJ, Ressler SJ, Larsen M, Tuxhorn JA, Yang F, Dang TD, Rowley DR 2003 Promotion of angiogenesis by ps20 in the differential reactive stroma prostate cancer xenograft model. Cancer Res 63:5859-5865